Annovis Bio GAAP EPS of -$0.40 beats by $0.05
Annovis Bio's GAAP EPS was reported at -$0.40, exceeding market expectations by $0.05, interpreted as a positive catalyst.
At the current price of $1.79, positioned between support at $1.55 and resistance at $1.98, an RSI of 64.4 accompanied by downward pressure and a 1.29x increase in trading volume have been observed; a strategy of entering after confirmation of a breakout above resistance, or waiting for a rebound following a test of support, may be considered.
Exit conditions: Take profit when the price reaches the resistance level of $1.98; stop loss and exit if the price falls to $1.55 or below.
RSI(14) 64.4, moving averages not in bullish alignment, trading volume at 1.29x the 20-day average, recent 7-day change of -4.3%
A stark contrast between the forecast of +2.1% and the actual result of -22.9% — despite positive news, selling pressure persisted and the stop-loss price of $1.55 was reached, suggesting that technical signals failed to fully reflect the market's price movement. Annovis Bio's positive EPS announcement, contrary to market expectations, triggered a wave of selling; despite an RSI of 64.4 and rising trading volume, the downtrend persisted, with the price breaking below the $1.55 support level serving as the primary cause. In terms of candlestick movement, the price fell to the September 3 close of 1.38, indicating that the stop-loss was triggered earlier than anticipated.
In the next trade, I will not enter based on news catalysts alone; instead, I will enter only after confirming that the price is above the resistance level of $1.98 and that trading volume exceeds the previous day's average. To limit risk, I will set the stop-loss with a wide margin below the recent low near the entry price, and I will apply dual technical filters, such as entering only after confirming moving average alignment and RSI thresholds. I will maintain the discipline of closing the position immediately upon the stop-loss level of $1.55 being reached, in order to minimize further losses.